大黄素
衰老
乳腺癌
细胞凋亡
癌症研究
乳腺癌化疗
癌症
活性氧
药理学
活力测定
化疗
癌细胞
医学
生物
内科学
生物化学
作者
Cong Zu,Guixin Qin,Chunshu Yang,Ning Liu,Anning He,Mingdi Zhang,Xinyu Zheng
标识
DOI:10.1016/j.bbrc.2018.09.045
摘要
The resistance to 5-FU often limits its clinical effectiveness on breast cancer treatment. Combination therapy thus is employed to overcome this treatment resistance. We here report a potent antitumor effect of Emodin at low dose on chemotherapy sensitivity of MCF-7 breast cancer cells.Cell viability, apoptosis, glutathiones (GSH) concentration and Reactive oxygen species (ROS) activity following Emodin and 5-FU treatment was assessed. Cellular senescence following combined treatment and silence of NRARP was examined by senescence-associated β-galactosidase analysis. Western blot analysis was used to determine changes in the expression of p21, p16, p27, E2F1 and NRARP.Low dose Emodin potentiates 5-FU-induced apoptosis of breast cancer cells, in association with inhibition of NRARP, resulting in cellular senescence. RNA interference of NRARP induced cellular senescence in MCF-7 breast cancer cells. Furthermore, the cellular senescence induced by Emodin and 5-FU treatment could be reverted by pcDNA-NRARP.These findings provide preclinical evidence for repurposing use of Emodin in combination with chemotherapeutic agents to treat breast cancer as an alternative salvage regimen.
科研通智能强力驱动
Strongly Powered by AbleSci AI